Increase in UK mental health drug prescribing noted by NHSBSA
The NHS Business Services Authority (NHSBSA) has released its annual Medicines Used in Mental Health official statistics, revealing an increase in prescribing across the following five British National Formulary (BNF) sections of medicines; antidepressants, hypnotics and anxiolytics, drugs for dementia, drugs used in psychoses and related disorders, and central nervous system (CNS) stimulants and drugs for attention deficit hyperactivity disorder (ADHD).
Both the number of items and identified patients increased in all five BNF medicine categories, and four out of five categories had higher numbers of identified patients in more deprived areas in England, with the exception of drugs for dementia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze